U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H15NO2
Molecular Weight 157.2102
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRANEXAMIC ACID

SMILES

NC[C@H]1CC[C@@H](CC1)C(O)=O

InChI

InChIKey=GYDJEQRTZSCIOI-LJGSYFOKSA-N
InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf

Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1). Tranexamic acid is used for use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.

CNS Activity

Curator's Comment: Tranexamic acid crosses the blood brain barrier.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
60.0 µM [IC50]
3.1 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LYSTEDA

Approved Use

LYSTEDA (tranexamic acid) Tablets is an antifibrinolytic indicated for the treatment of cyclic heavy menstrual bleeding.

Launch Date

5.36198414E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
16.41 μg/mL
1300 mg 3 times / day multiple, oral
dose: 1300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRANEXAMIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
13.83 μg/mL
1300 mg single, oral
dose: 1300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRANEXAMIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
77.67 μg × h/mL
1300 mg 3 times / day multiple, oral
dose: 1300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRANEXAMIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
80.19 μg × h/mL
1300 mg single, oral
dose: 1300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRANEXAMIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.08 h
1300 mg single, oral
dose: 1300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRANEXAMIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
97%
1300 mg single, oral
dose: 1300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRANEXAMIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1300 mg 3 times / day steady, oral
Recommended
Dose: 1300 mg, 3 times / day
Route: oral
Route: steady
Dose: 1300 mg, 3 times / day
Sources:
healthy, 18 - 49 years
n = 232
Health Status: healthy
Condition: cyclic heavy menstrual bleeding
Age Group: 18 - 49 years
Sex: F
Population Size: 232
Sources:
Other AEs: Headache, Nasal disorder NOS...
Other AEs:
Headache (50.4%)
Nasal disorder NOS (25.4%)
Back pain (20.7%)
Abdominal pain (19.8%)
Musculoskeletal pain (11.2%)
Arthralgia (6.9%)
Muscle cramps (6.5%)
Migraine (6%)
Anemia (5.6%)
Fatigue (5.2%)
Sources:
1 g 4 times / day steady, oral
Overdose
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Sources:
unhealthy, 45 years
n = 1
Health Status: unhealthy
Condition: chronic kidney disease
Age Group: 45 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Convulsions generalized...
AEs leading to
discontinuation/dose reduction:
Convulsions generalized (1 patient)
Sources:
2000 mg 1 times / day steady, intravenous
Recommended
Dose: 2000 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 2000 mg, 1 times / day
Sources:
unhealthy, 56 years
n = 1
Health Status: unhealthy
Condition: emergency operation for a bleeding ulcer of the stomach and duodenum
Age Group: 56 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Blindness...
AEs leading to
discontinuation/dose reduction:
Blindness (1 patient)
Sources:
250 mg 2 times / day steady, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: steady
Dose: 250 mg, 2 times / day
Sources:
unhealthy, mean 40.7 years
n = 561
Health Status: unhealthy
Condition: Melasma
Age Group: mean 40.7 years
Sex: M+F
Population Size: 561
Sources:
Disc. AE: Deep vein thrombosis leg...
AEs leading to
discontinuation/dose reduction:
Deep vein thrombosis leg (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Musculoskeletal pain 11.2%
1300 mg 3 times / day steady, oral
Recommended
Dose: 1300 mg, 3 times / day
Route: oral
Route: steady
Dose: 1300 mg, 3 times / day
Sources:
healthy, 18 - 49 years
n = 232
Health Status: healthy
Condition: cyclic heavy menstrual bleeding
Age Group: 18 - 49 years
Sex: F
Population Size: 232
Sources:
Abdominal pain 19.8%
1300 mg 3 times / day steady, oral
Recommended
Dose: 1300 mg, 3 times / day
Route: oral
Route: steady
Dose: 1300 mg, 3 times / day
Sources:
healthy, 18 - 49 years
n = 232
Health Status: healthy
Condition: cyclic heavy menstrual bleeding
Age Group: 18 - 49 years
Sex: F
Population Size: 232
Sources:
Back pain 20.7%
1300 mg 3 times / day steady, oral
Recommended
Dose: 1300 mg, 3 times / day
Route: oral
Route: steady
Dose: 1300 mg, 3 times / day
Sources:
healthy, 18 - 49 years
n = 232
Health Status: healthy
Condition: cyclic heavy menstrual bleeding
Age Group: 18 - 49 years
Sex: F
Population Size: 232
Sources:
Nasal disorder NOS 25.4%
1300 mg 3 times / day steady, oral
Recommended
Dose: 1300 mg, 3 times / day
Route: oral
Route: steady
Dose: 1300 mg, 3 times / day
Sources:
healthy, 18 - 49 years
n = 232
Health Status: healthy
Condition: cyclic heavy menstrual bleeding
Age Group: 18 - 49 years
Sex: F
Population Size: 232
Sources:
Fatigue 5.2%
1300 mg 3 times / day steady, oral
Recommended
Dose: 1300 mg, 3 times / day
Route: oral
Route: steady
Dose: 1300 mg, 3 times / day
Sources:
healthy, 18 - 49 years
n = 232
Health Status: healthy
Condition: cyclic heavy menstrual bleeding
Age Group: 18 - 49 years
Sex: F
Population Size: 232
Sources:
Anemia 5.6%
1300 mg 3 times / day steady, oral
Recommended
Dose: 1300 mg, 3 times / day
Route: oral
Route: steady
Dose: 1300 mg, 3 times / day
Sources:
healthy, 18 - 49 years
n = 232
Health Status: healthy
Condition: cyclic heavy menstrual bleeding
Age Group: 18 - 49 years
Sex: F
Population Size: 232
Sources:
Headache 50.4%
1300 mg 3 times / day steady, oral
Recommended
Dose: 1300 mg, 3 times / day
Route: oral
Route: steady
Dose: 1300 mg, 3 times / day
Sources:
healthy, 18 - 49 years
n = 232
Health Status: healthy
Condition: cyclic heavy menstrual bleeding
Age Group: 18 - 49 years
Sex: F
Population Size: 232
Sources:
Migraine 6%
1300 mg 3 times / day steady, oral
Recommended
Dose: 1300 mg, 3 times / day
Route: oral
Route: steady
Dose: 1300 mg, 3 times / day
Sources:
healthy, 18 - 49 years
n = 232
Health Status: healthy
Condition: cyclic heavy menstrual bleeding
Age Group: 18 - 49 years
Sex: F
Population Size: 232
Sources:
Muscle cramps 6.5%
1300 mg 3 times / day steady, oral
Recommended
Dose: 1300 mg, 3 times / day
Route: oral
Route: steady
Dose: 1300 mg, 3 times / day
Sources:
healthy, 18 - 49 years
n = 232
Health Status: healthy
Condition: cyclic heavy menstrual bleeding
Age Group: 18 - 49 years
Sex: F
Population Size: 232
Sources:
Arthralgia 6.9%
1300 mg 3 times / day steady, oral
Recommended
Dose: 1300 mg, 3 times / day
Route: oral
Route: steady
Dose: 1300 mg, 3 times / day
Sources:
healthy, 18 - 49 years
n = 232
Health Status: healthy
Condition: cyclic heavy menstrual bleeding
Age Group: 18 - 49 years
Sex: F
Population Size: 232
Sources:
Convulsions generalized 1 patient
Disc. AE
1 g 4 times / day steady, oral
Overdose
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Sources:
unhealthy, 45 years
n = 1
Health Status: unhealthy
Condition: chronic kidney disease
Age Group: 45 years
Sex: F
Population Size: 1
Sources:
Blindness 1 patient
Disc. AE
2000 mg 1 times / day steady, intravenous
Recommended
Dose: 2000 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 2000 mg, 1 times / day
Sources:
unhealthy, 56 years
n = 1
Health Status: unhealthy
Condition: emergency operation for a bleeding ulcer of the stomach and duodenum
Age Group: 56 years
Sex: M
Population Size: 1
Sources:
Deep vein thrombosis leg 1 patient
Disc. AE
250 mg 2 times / day steady, oral
Recommended
Dose: 250 mg, 2 times / day
Route: oral
Route: steady
Dose: 250 mg, 2 times / day
Sources:
unhealthy, mean 40.7 years
n = 561
Health Status: unhealthy
Condition: Melasma
Age Group: mean 40.7 years
Sex: M+F
Population Size: 561
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
yes
yes
Tox targets
PubMed

PubMed

TitleDatePubMed
The emerging periplasm-localized subclass of AroQ chorismate mutases, exemplified by those from Salmonella typhimurium and Pseudomonas aeruginosa.
2001
Treatment of recurrent severe hemoptysis in cystic fibrosis with tranexamic acid.
2001
Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease.
2001 Apr
No increased risk of venous thrombosis in women taking tranexamic acid.
2001 Aug
Tranexamic acid in off-pump coronary surgery: a preliminary, randomized, double-blind, placebo-controlled study.
2001 Aug
Convulsive seizures following subdural application of fibrin sealant containing tranexamic acid in a rat model.
2001 Aug
The effect of tranexamic acid on cochlear blood flow in guinea pigs measured by laser Doppler flowmetry.
2001 Aug
Dental extractions in patients maintained on oral anticoagulant therapy: comparison of INR value with occurrence of postoperative bleeding.
2001 Dec
Possible role of plasminogen activator in the occurrence of profuse watery rhinorrhea after topical application of epinephrine to the nasal mucosa.
2001 Dec
Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins.
2001 Dec
Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome.
2001 Dec
Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery.
2001 Dec 1
Systemic hemostatic medications for reducing surgical blood loss.
2001 Jul-Aug
Re: Webster K, Wilde J. Management of anticoagulation in patients with prosthetic heart valves undergoing oral and maxillofacial operations. Br J Oral Maxillofac Surg 2000; 38: 124-126.
2001 Jun
Successful arthroscopic treatment of pigmented villonodular synovitis of the knee in a patient with congenital deficiency of plasminogen activator inhibitor-1 and recurrent haemarthrosis.
2001 Mar-Apr
Enhanced thrombolysis induced by argatroban or activated protein C in the presence or absence of staphylokinase, measured in an in vivo animal model using mesenteric arterioles.
2001 Mar-Apr
The effect of tourniquet application, tranexamic acid, and desmopressin on the procoagulant and fibrinolytic systems during total knee replacement.
2001 Nov
Method to measure in vivo blood fibrinolytic activity with a (125)I-fibrin coated aorta loop validated with agents which affect blood fibrinolytic activity.
2001 Nov 1
Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
2001 Oct
A comparative study of the postoperative allogeneic blood-sparing effects of tranexamic acid and of desmopressin after total knee replacement.
2001 Oct
An unusual cause of bleeding.
2001 Oct 27
Antifibrinolytic agents and desmopressin as hemostatic agents in cardiac surgery.
2001 Sep
Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points.
2001 Sep
Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
2001 Sep 20
Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII.
2002
Is the kaolin or celite activated clotting time affected by tranexamic acid?
2002 Aug
Differential effects of aprotinin and tranexamic acid on endotoxin desensitization of blood cells induced by circulation through an isolated extracorporeal circuit.
2002 Aug
Pharmacokinetics of tranexamic acid during cardiopulmonary bypass.
2002 Aug
Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.
2002 Jan
[Tranexamic acid reduces blood loss and the need of blood transfusion after knee arthroplasty].
2002 Jan 14
Rendu-Osler-Weber disease: experience with 56 patients.
2002 Jul-Sep
Menorrhagia.
2002 Jun
Clinical management of hereditary angio-oedema in children.
2002 Jun
Hemostatic effects of tranexamic acid in elective thoracic aortic surgery: a prospective, randomized, double-blind, placebo-controlled study.
2002 Jun
Development of novel topical tranexamic acid liposome formulations.
2002 Mar 20
Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia.
2002 May
Impact of hematocrit value after coronary artery surgery on perioperative myocardial infarction rate.
2002 Oct
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: can also be injected http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=TRANEXAMIC%20ACID
1,300 mg (two 650 mg tablets) three times a day (3,900 mg/day) for a maximum of 5 days during monthly menstruation
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Whole human blood was used
0.03 mg/mL Tranexamic acid reduced the fibrinogen fall induced by t-PA 20 nM from 43% to 14%.
Name Type Language
TRANEXAMIC ACID
EP   INCI   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   INCI   USAN  
Official Name English
TRANEXAMIC ACID [USP MONOGRAPH]
Common Name English
TRANEXAMIC ACID [USP-RS]
Common Name English
TRANS-4-(AMINOMETHYL)CYCLOHEXANECARBOXYLIC ACID
Systematic Name English
CYCLOHEXANECARBOXYLIC ACID, 4-(AMINOMETHYL)-, TRANS-
Systematic Name English
CYCLO-F
Brand Name English
tranexamic acid [INN]
Common Name English
RP-18429
Code English
AMCHA
Common Name English
TRANEXAMIC ACID [USAN]
Common Name English
TRANSAMIN
Brand Name English
LYSTEDA
Brand Name English
NSC-291305
Code English
TRANEXAMIC ACID [USP IMPURITY]
Common Name English
TRANEXAMIC ACID [ORANGE BOOK]
Common Name English
HAEMATRIX
Brand Name English
CYCLOCAPRON
Common Name English
CL65336
Code English
TRANEXAMIC ACID [MART.]
Common Name English
CL-65336
Code English
CYKLOKAPRON
Brand Name English
TRANS-AMCHA
Code English
TRANEXAMIC ACID [INCI]
Common Name English
ESPERCIL
Brand Name English
TRANEXAMIC ACID [VANDF]
Common Name English
TRANEXAMIC ACID [EP MONOGRAPH]
Common Name English
TRANEXAMIC ACID [JAN]
Common Name English
LB1148
Code English
CYCLOKAPRON
Common Name English
Tranexamic acid [WHO-DD]
Common Name English
TRANEXAMIC ACID [MI]
Common Name English
FEMSTRUAL
Brand Name English
TRANS AMCHA
Code English
RIKAVARIN
Brand Name English
Classification Tree Code System Code
LIVERTOX 988
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
WHO-ATC B02AA02
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
WHO-VATC QB02AA02
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
NDF-RT N0000175632
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
NDF-RT N0000175634
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 10.2
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
NDF-RT N0000175632
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
FDA ORPHAN DRUG 8885
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
NCI_THESAURUS C78311
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
Code System Code Type Description
DRUG CENTRAL
2713
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
NCI_THESAURUS
C47765
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
RXCUI
10691
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY RxNorm
EVMPD
SUB11214MIG
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
IUPHAR
6573
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
ChEMBL
CHEMBL877
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
MERCK INDEX
M11000
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY Merck Index
LACTMED
Tranexamic Acid
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
WIKIPEDIA
TRANEXAMIC ACID
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
ECHA (EC/EINECS)
214-818-2
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
NSC
291305
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
EPA CompTox
DTXSID3045350
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
DRUG BANK
DB00302
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
RS_ITEM_NUM
1672745
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
DAILYMED
6T84R30KC1
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
MESH
D014148
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
CAS
1197-18-8
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
INN
2060
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
CHEBI
48669
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
FDA UNII
6T84R30KC1
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY
SMS_ID
100000091040
Created by admin on Thu Jul 06 22:22:32 UTC 2023 , Edited by admin on Thu Jul 06 22:22:32 UTC 2023
PRIMARY